Imigran

Sumatriptan, the active ingredient in Imigran, is a Triptan presented as a tablet for oral use. It treats acute migraine attacks in adults, providing relief from headache pain and associated symptoms. GNH USA supplies Imigran as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imigran (sumatriptan) is indicated for the acute treatment of migraine, a vascular headache disorder.

Migraine (with or without aura): rapid relief of headache pain, nausea, photophobia and phonophobia. Migraine with aura: alleviates headache and visual disturbances that accompany the aura phase. Cluster headache: aborts attacks of episodic cluster headache when other therapies are insufficient.

Common Side Effects: - Chest tightness or pressure - Tingling or numbness in fingers or face - Warmth or flushing sensation - Dizziness or light‑headedness - Nausea or mild stomach upset - Fatigue or drowsiness

Serious or Rare Side Effects: - Coronary vasospasm or myocardial ischemia - Severe hypertension or hypertensive crisis - Serotonin syndrome, especially with serotonergic drugs - Allergic reactions such as rash, swelling or anaphylaxis - Stroke or transient ischemic attack - Severe arrhythmias or cardiac arrest

Before using Imigran, consider the following precautions: - Cardiovascular assessment: evaluate history of heart disease or risk factors. - Hypertension: avoid if uncontrolled high blood pressure is present. - Hepatic impairment: use with caution in patients with liver dysfunction. - Drug interactions: review concomitant serotonergic medications. - Driving and operating machinery: be cautious if dizziness or fatigue occurs. - Store at room temperature: keep in the original packaging, protect from moisture and heat.

Imigran may interact with several drug classes.

Major Interactions (Avoid): - MAO inhibitors: risk of serotonin syndrome. - Other triptans or ergot alkaloids: may cause excessive vasoconstriction. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase sumatriptan plasma levels.

Moderate Interactions (Monitor Closely): - SSRIs, SNRIs, or other serotonergic agents: monitor for serotonin toxicity. - Antihypertensive agents: additive blood pressure lowering effect. - Oral contraceptives: may increase risk of vascular events.